UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

Therapeutic advances in neurological disorders, 2017-10, Vol.10 (10), p.343-359

2017

Volltextzugriff (PDF)

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation

Journal of neuroinflammation, 2017-02, Vol.14 (1), p.41-41, Article 41

2017

Volltextzugriff (PDF)

Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study

Journal of medical Internet research, 2012-10, Vol.14 (5), p.e135-e135

2012

Volltextzugriff (PDF)

Cortisol awakening response is linked to disease course and progression in multiple sclerosis

PloS one, 2013-04, Vol.8 (4), p.e60647-e60647

2013

Volltextzugriff (PDF)

Emotionen im Feld: Gespräche zur Ethnografie, Primatografie und Reiseliteratur

1, 2019

Volltextzugriff (PDF)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

Journal of neuroinflammation, 2017-08, Vol.14 (1), p.172-172, Article 172

2017

Volltextzugriff (PDF)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach

BMC neurology, 2016-08, Vol.16 (1), p.124-124, Article 124

2016

Volltextzugriff (PDF)

Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis

Expert opinion on pharmacotherapy, 2017-10, Vol.18 (15), p.1649-1660

2017

Volltextzugriff (PDF)

Treatment optimization in multiple sclerosis: how do we apply emerging evidence?

Expert review of clinical immunology, 2017-06, Vol.13 (6), p.509-511

2017

Volltextzugriff (PDF)

Natalizumab during pregnancy and lactation

Multiple sclerosis, 2018-10, Vol.24 (12), p.1627-1634

2018

Volltextzugriff (PDF)

Management of fingolimod in clinical practice

Clinical neurology and neurosurgery, 2013-12, Vol.115 (S1), p.S60-S64

2013

Volltextzugriff (PDF)

Response to: S. Sega-Jazbec et al.: “Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis” Multiple Sclerosis and Related Disorders 2017

Multiple sclerosis and related disorders, 2017-10, Vol.17, p.177-178

2017

Volltextzugriff (PDF)

Laquinimod in the treatment of relapsing remitting multiple sclerosis

Expert opinion on drug metabolism & toxicology, 2016-06, Vol.12 (6), p.701-709

2016

Volltextzugriff (PDF)

Effects of Multiple Sclerosis Therapies on the Gut Immune System (P6.191)

Neurology, 2016-04, Vol.86 (16_supplement)

2016

Volltextzugriff (PDF)

Modern communication technology skills of patients with multiple sclerosis

Multiple sclerosis, 2013-08, Vol.19 (9), p.1240-1241

2013

Volltextzugriff (PDF)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS

Neurology : neuroimmunology & neuroinflammation, 2016-06, Vol.3 (3), p.e228-e228

2016

Volltextzugriff (PDF)

Neuroborreliosis during natalizumab treatment in multiple sclerosis

Neurology, 2013-09, Vol.81 (11), p.1012-1014

2013

Volltextzugriff (PDF)

Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Multiple sclerosis, 2018-05, Vol.24 (6), p.820-822

2018

Volltextzugriff (PDF)

Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

Multiple sclerosis, 2018-09, Vol.24 (10), p.1337-1346

2018

Volltextzugriff (PDF)

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

BMC neurology, 2016-07, Vol.16 (1), p.109-109, Article 109

2016

Volltextzugriff (PDF)

Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients

Journal of Neural Transmission, 2013-09, Vol.120 (Suppl 1), p.61-66

2013

Volltextzugriff (PDF)

parasite fauna of stray domestic cats (Felis catus) in Dubai, United Arab Emirates

Parasitology research (1987), 2009-07, Vol.105 (1), p.125-134

2009

Volltextzugriff (PDF)

SlanDCs as Crucial Target of the MS-Immunmodulator Laquinimod (P05.156)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Effects of Long-Term Natalizumab Treatment on Cell Bound Natalizumab and Very Late Antigen–4 Expression (P05.190)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Immunomodulatory Treatment Strategies Differently Affect Dendritic Cells in Multiple Sclerosis Patients (S11.006)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

1 – 25 von 4.472

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.573)
Mit Volltextzugriff
(3.923)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.629)
Life Sciences & Biomedicine
(2.162)
Humans
(1.468)
Female
(824)
Male
(751)
Adult
(479)
Animals
(464)
Middle Aged
(447)
Biological And Medical Sciences
(375)
Physical Sciences
(350)
Aged
(334)
Medical Sciences
(261)
Oncology
(242)
Biochemistry & Molecular Biology
(237)
Neurosciences & Neurology
(237)
Medicine
(227)
Mice
(225)
Patients
(221)
Science & Technology - Other Topics
(208)
Multidisciplinary Sciences
(190)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation

Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study

Cortisol awakening response is linked to disease course and progression in multiple sclerosis

Emotionen im Feld: Gespräche zur Ethnografie, Primatografie und Reiseliteratur

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach

Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis

Treatment optimization in multiple sclerosis: how do we apply emerging evidence?

Natalizumab during pregnancy and lactation

Management of fingolimod in clinical practice

Response to: S. Sega-Jazbec et al.: “Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis” Multiple Sclerosis and Related Disorders 2017

Laquinimod in the treatment of relapsing remitting multiple sclerosis

Effects of Multiple Sclerosis Therapies on the Gut Immune System (P6.191)

Modern communication technology skills of patients with multiple sclerosis

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS

Neuroborreliosis during natalizumab treatment in multiple sclerosis

Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients

parasite fauna of stray domestic cats (Felis catus) in Dubai, United Arab Emirates

SlanDCs as Crucial Target of the MS-Immunmodulator Laquinimod (P05.156)

Effects of Long-Term Natalizumab Treatment on Cell Bound Natalizumab and Very Late Antigen–4 Expression (P05.190)

Immunomodulatory Treatment Strategies Differently Affect Dendritic Cells in Multiple Sclerosis Patients (S11.006)

Suchergebnisse filtern